Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review

BACKGROUND: Programmed cell death-1 (PD-1) inhibitor has been indicated for many types of malignancies. However, these inhibitors also cause immune-related adverse events. Hepatobiliary disorder is a phenotype of immune-related adverse event affecting 0%–4.5% of patients treated with PD-1 inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Onoyama, Takumi, Takeda, Yohei, Yamashita, Taro, Hamamoto, Wataru, Sakamoto, Yuri, Koda, Hiroki, Kawata, Soichiro, Matsumoto, Kazuya, Isomoto, Hajime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Systematic Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969883/
https://www.ncbi.nlm.nih.gov/pubmed/31988594
http://dx.doi.org/10.3748/wjg.v26.i3.353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969883/
https://www.ncbi.nlm.nih.gov/pubmed/31988594
http://dx.doi.org/10.3748/wjg.v26.i3.353

Ejemplares similares